December 2, 2022
Loading...
You are here:  Home  >  Banking & Finance  >  Current Article

Amgen’s investment in Neumora marks a return to neuroscience research

IN THIS ARTICLE

Two years after ending its own internal neuroscience research and early development programs, Thousand Oaks-based Amgen has found a way to get the sector back into its portfolio. Neumora Therapeutics, a Massachusetts-based developer of drugs for brain diseases, officially launched on Oct. 7, with a strategic partnership between the two companies that includes global rights…

Subscribe

    This article is only available to Business Times subscribers
  • Subscribers: or REGISTER for complete digital access.
  • Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
  • Check the STATUS of your Subscription Account.